“…Clinical success may also be enhanced by uncovering novel strategies. In this context, it is worth noting that, although not tested against cancer yet, intracellular allosteric ligands have also been synthesized for many other chemokine receptors than those discussed in the main text, including CCR1, CCR4, CCR5, and CX3CR1 [77][78][79][80]. Long-residence time antagonists might provide another strategy to inhibit chemokine receptors in an insurmountable manner, such as those described for CCR2 [81,82].…”